The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis

BACKGROUND: Erb-b2 receptor tyrosine kinase 2 (ErbB2/HER2) mutation has been found in approximately 2–4% of non-small cell lung cancer (NSCLC) patients and has been identified as one of carcinogenic mutations. Afatinib, a member of irreversible HER family inhibitor, has been investigated by a number...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Niya, Zhao, Jie, Huang, Xiu, Shen, Hui, Li, Wen, Xu, Zhihao, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797916/
https://www.ncbi.nlm.nih.gov/pubmed/35117726
http://dx.doi.org/10.21037/tcr.2020.04.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797916/
https://www.ncbi.nlm.nih.gov/pubmed/35117726
http://dx.doi.org/10.21037/tcr.2020.04.09

Ejemplares similares